IRON
Disc Medicine, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | +7 | 22.99M | $1.68B | +9 | −2 |
| Q1 2026 | 79 | +1 | 22.38M | $1.43B | +7 | −6 |
| Q4 2025 | 77 | -1 | 22.10M | $1.75B | +1 | −2 |
| Q3 2025 | 17 | +3 | 15.61M | $1.03B | +3 | — |
| Q2 2025 | 11 | -1 | 11.75M | $622.02M | +1 | −2 |
| Q1 2025 | 9 | -1 | 6.07M | $301.51M | — | −1 |
| Q4 2024 | 10 | +3 | 5.16M | $327.26M | +3 | — |
| Q3 2024 | 6 | -1 | 5.16M | $253.75M | — | −1 |
| Q2 2024 | 7 | — | 5.00M | $225.18M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 1.76M | — | $79.17M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.76M | — | $79.17M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.76M | — | $79.17M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.76M | — | $79.17M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.76M | — | $79.17M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.76M | — | $79.17M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 1.12M | — | $50.58M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 1.12M | — | $50.58M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 761.43K | — | $34.32M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 618.50K | — | $27.88M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 403.74K | — | $18.20M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 403.74K | — | $18.20M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 321.52K | — | $14.49M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 321.52K | — | $14.49M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 12.30K | — | $554,361 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Marshall Wace ✦ | 12.30K | — | $554,361 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 203 holders, 40.63M shares, $2.48B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 8.40K sh · $656,091
Officer, Director · 12.71K sh · $1.01M
Officer, Director · 11.89K sh · $949,162
Officer · 804 sh · $66,445
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology